EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort

Tomoya Kawakami, Sho Masui, Akira Onishi, Hideo Onizawa, Takayuki Fujii, Kosaku Murakami iD, Koichi Murata iD, Masao Tanaka, Takashi Shimada, Shunsaku Nakagawa, Shuichi Matsuda, Akio Morinobu und 2 weitere

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae018 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Tomoya Kawakami und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Etanercept, Biosimilar Pharmaceuticals, Antirheumatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Biosimilars are anticipated to be widely used in the treatment of rheumatoid arthritis (RA), owing to their cost efficiency; LBEC0101 was the first etanercept (ETN) biosimilar approved in Japan. However, there are limited real-world data comparing its safety and effectiveness with those of a reference product.

Methods

This study used data from the Kyoto University Rheumatoid Arthritis Management Alliance cohort, including patients with RA who received ETN therapy—ETN reference product (ETN-RP) or LBEC0101—between 2015 and 2021. Serum ETN levels were measured using liquid chromatography–tandem mass spectrometry.

Results

The 1-year continuation rates of ETN-RP and LBEC0101 were 58.7% and 74.4%, respectively. Effectiveness of treatment was evaluated in 18 patients; both products significantly reduced the 28-joint RA disease activity score and erythrocyte sedimentation rate (DAS28-ESR). Moreover, to determine equivalence, we analysed 11 patients who switched from ETN-RP to LBEC0101; the DAS28-ESR and serum ETN levels before and after switching were not significantly different.

Conclusions

This real-world cohort study confirmed that the biosimilar of ETN, LBEC0101, was comparable to the reference product in terms of continuation rate, effectiveness at initiation of introduction, and effect persistence before and after switching in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidEtanerceptBiosimilar PharmaceuticalsAntirheumatic AgentsHumansFemaleMaleMiddle AgedAgedTreatment OutcomeJapanCohort StudiesAdult

Stichwörter der Autor:innen

BiosimilarLBEC0101etanerceptreal-world datarheumatoid arthritis

Substanzen

EtanerceptBiosimilar PharmaceuticalsAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan.
  • Division of Integrative Clinical Pharmacology, Faculty of Pharmacy, Keio University, Tokyo, Japan.
  • Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • SHIMADZU Corporation, Kyoto, Japan.

ORCID-Profile: Kosaku Murakami, Koichi Murata, Atsushi Yonezawa

Zitieren

APA

Kawakami, T., Masui, S., Onishi, A., Onizawa, H., Fujii, T., Murakami, K., Murata, K., Tanaka, M., Shimada, T., Nakagawa, S., Matsuda, S., Morinobu, A., Terada, T., & Yonezawa, A. (2024). Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort. Modern Rheumatology. https://doi.org/10.1093/mr/roae018

Vancouver

Kawakami T, Masui S, Onishi A, Onizawa H, Fujii T, Murakami K, et al. Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort. Modern Rheumatology. 2024. doi:10.1093/mr/roae018

BibTeX
@article{Kawakami2024,
  author = {Kawakami, Tomoya and Masui, Sho and Onishi, Akira and Onizawa, Hideo and Fujii, Takayuki and Murakami, Kosaku and Murata, Koichi and Tanaka, Masao and Shimada, Takashi and Nakagawa, Shunsaku and Matsuda, Shuichi and Morinobu, Akio and Terada, Tomohiro and Yonezawa, Atsushi},
  title = {Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae018}
}
Kostenlos starten →